Treatment of Dementia With Bosutinib: An Open-Label Study of a Tyrosine Kinase Inhibitor.
Neurol Clin Pract
california; santa monica; pacific neuroscience institute
Objective: The pursuit of an effective therapeutic intervention for dementia has inspired interest in the class of medications known as tyrosine kinase inhibitors such as bosutinib.
Methods: Thirty-one patients with probable Alzheimer dementia or Parkinson spectrum disorder with dementia completed 12 months of bosutinib therapy and an additional 12 months of follow-up. The Clinical Dementia Rating scale (as estimated by the Quick Dementia Rating System [QDRS]) was the primary cognitive status outcome measure. Secondary outcome measures included the Repeatable Battery Assessment of Neuropsychological Status (RBANS) and the Montreal Cognitive Assessment. Cox regression methods were used to compare results with population-based estimates of cognitive decline.
Results: The present article reports on cognitive outcomes obtained at 12 months for 31 participants and up to 24 months for a 16-participant subset. Safety and tolerability of bosutinib were confirmed among the study population (M
Conclusions: Results support an overall positive outcome after 1 year of bosutinib. Future studies should explore the relationship between tyrosine kinases and neurodegenerative pathology as well as related avenues of treatment.
Neurosciences (Brain & Spine)
Mahdavi, Kennedy D; Jordan, Sheldon E; Barrows, Hannah R; Pravdic, Maša; Habelhah, Barshen; Evans, Natalie E; Blades, Robin B; Iovine, Jessica J; Becerra, Sergio A; Steiner, Rachel A; Chang, Marisa; Kesari, Santosh; Bystritsky, Alexander; O'Connor, Ed; Gross, Hyman; Pereles, F Scott; Whitney, Mike; and Kuhn, Taylor, "Treatment of Dementia With Bosutinib: An Open-Label Study of a Tyrosine Kinase Inhibitor." (2021). Articles, Abstracts, and Reports. 5330.